Sabine D. Brookman-May, Senior Vice President, Therapeutic Area Head Urologic Oncology at Aura Biosciences, shared on X:
“Papillary disease HR NMIBC data from Sunrise1 presented by Félix Guerrero-Ramos:
DFS rates at 6 and 9 months 85 and 81%
consistent rates in Ta + T1
Data from SR5 to be awaited to compare outcomes in %BCG experienced papillary NMIBC in a randomized phase 3″
More posts featuring Sabine Brookman-May on OncoDaily.
